Jeffrey A Ledbetter

US Patent:

20100330089, Dec 30, 2010

Filed:

Jun 12, 2008

Appl. No.:

12/664166

Inventors:

Nitin K. Damle - Upper Saddle River NJ, US
Lioudmila Tchistiakova - Andover MA, US
Kyriaki Dunussi-Joannopoulos - Belmont MA, US
Sandy Alexander Simon - Seattle WA, US
William Brady - Bothell WA, US
Laura Sue Grosmaire - Hobart WA, US
Jeffrey Alan Ledbetter - Shoreline WA, US

Assignee:

Wyeth - Madison NJ
Trubion Pharmaceuticals Inc. - Seattle WA

International Classification:

A61K 39/395
C07K 16/28
C07H 21/00
C12N 15/63
C12N 5/10
C12P 21/02
G01N 33/566
A61P 37/02
A61P 29/00
A61P 25/00
A61P 35/00

US Classification:

4241351, 5303873, 4241331, 536 2353, 4353201, 435328, 435 696, 435 724

Abstract:

The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.